189268-35-7

Upstream product

• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 149976-78-3 2,6-dichloro-1-methanesulfonyloxymethyl-3-nitrobenzene 
• 167834-56-2 8-(2,6-Dichloro-3-nitro-benzyloxy)-2-methyl-quinoline 
• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 
• 179625-53-7 8-(2,6-dichloro-3-aminobenzyloxy)-2-methylquinoline 

Downstream Products

• 189268-37-9 1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)-phenyl]-2-cyanopyrrole 
• 189268-39-1 2-aminomethyl-1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)phenyl]pyrrole 
• 189268-50-6 2-[(E)-3-(6-carboxypyridin-3-yl)acryloylaminomethyl]-1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)phenyl]pyrrole 
• 189268-49-3 1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)phenyl]-2-[(E)-3-(6-ethoxycarbonylpyridin-3-yl)acryloylaminomethyl]pyrrole 

Relevant academic research and scientific papers

Heterocyclic compounds as bradykinin antagonists

This invention relates to a compound of the formula: wherein A1is lower alkylene, R1is substituted quinolyl, etc., R2is hydrogen, halogen or lower alkyl, R3is halogen or lower alkyl, and R4is a group

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation

In recent articles we reported the identification of a series of 8- [[2,6-dichloro-3-[N-methyl-N-[(E)- (substituted)acryloylglycyl]amino]benzyl]oxy]-2-methylimidazo[1,2- a]pyridines as the first orally active non-peptide bradykinin (BK) B2 rece